Abbegail Degelow
Family · Nashville, TNNPI 1841964368
Payments from drug & device makers
Across 464 payments — averaging $25.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Insulet Corporation$1K
- Lilly USA, LLC$1K
- Novo Nordisk$1K
- Cequr Corporation$956
- Xeris Pharmaceuticals, Inc.$659
- plus $5K from 31 others
What the payments were for
- Travel & lodging$1,53613%
- Food & beverage$10,41987%
- Education$430%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 15 | $1,969 |
| Insulet Corporation | 43 | $1,333 |
| Lilly USA, LLC | 56 | $1,224 |
| Novo Nordisk | 54 | $1,067 |
| Cequr Corporation | 3 | $956 |
| Xeris Pharmaceuticals, Inc. | 30 | $659 |
| Sanofi-aventis U.S. LLC | 27 | $519 |
| Amgen | 20 | $351 |
| Bayer | 14 | $305 |
| Abbott | 38 | $286 |
| Mannkind Corporation | 10 | $274 |
| BETA Bionics, Inc. | 10 | $252 |
| Dexcom, Inc. | 22 | $227 |
| AstraZeneca(2 entities) | 11 | $221 |
| Corcept Therapeutics | 10 | $214 |
| AbbVie | 11 | $205 |
| Sequel Med Tech, LLC | 7 | $199 |
| Radius Health, Inc. | 9 | $178 |
| Amneal Pharmaceuticals LLC | 8 | $161 |
| Boehringer Ingelheim | 8 | $158 |
| Tandem Diabetes Care, Inc. | 5 | $133 |
| Novartis | 6 | $131 |
| Kyowa Kirin, Inc. | 6 | $122 |
| Ascensia Diabetes Care US Inc. | 5 | $119 |
| IBSA Pharma Inc. | 6 | $106 |
| Ascendis Pharma Endocrinology Inc | 5 | $100 |
| Chiesi USA, Inc. | 4 | $84 |
| Amphastar Pharmaceuticals, Inc. | 4 | $82 |
| Amryt Pharma Holdings Ltd | 3 | $71 |
| Ultragenyx Pharmaceutical Inc. | 2 | $56 |
| Madrigal Pharmaceuticals | 2 | $54 |
| Pfizer | 2 | $50 |
| Rhythm Pharmaceuticals, Inc. | 2 | $41 |
| Recordati_rare_diseases_inc. | 2 | $36 |
| Acella Pharmaceuticals, LLC | 1 | $23 |
| Tolmar, Inc. | 1 | $23 |
| Genentech USA, Inc. | 2 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 780G$1,503
- CeQur Simplicity$956
- Omnipod$460
How this compares
$11,998 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 269 | $397,674 |
| MounjaroTirzepatide | 131 | $181,370 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 88 | $124,310 |
| JardianceEmpagliflozin | 92 | $118,559 |
| Tresiba Flextouch U-100Insulin Degludec | 94 | $60,613 |
| FarxigaDapagliflozin Propanediol | 43 | $51,895 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 37 | $49,722 |
| TrulicityDulaglutide | 28 | $47,153 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 29 | $46,132 |
| Humalog Kwikpen U-200Insulin Lispro | 16 | $39,716 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $38,081 |
| RybelsusSemaglutide | 13 | $28,048 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 15 | $24,157 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 56 | $19,106 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 33 | $14,527 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog, Tresiba | $1,067 | $439,137311 claims |
| Lilly USA, LLCMounjaro, Trulicity, Insulin Lispro | $1,224 | $230,811179 claims |
| Boehringer IngelheimJardiance | $158 | $118,55992 claims |
| AstraZenecaFarxiga | $221 | $51,89543 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $519 | $49,72237 claims |
| AbbVieSynthroid | $205 | $96212 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $161 | $46756 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.
Other family in Nashville
- Tamera ThoenerNashville$254K
- Jennifer WilliamsNashville$213K
- Lori LankfordNashville$148K
- Melissa RikalNashville$144K
- Nicole DelliseNashville$67K
- Lesley BallanceNashville$63K
- Jeffrey WoodsNashville$38K
- Courtney HavillNashville$35K
- Collette UtleyNashville$28K
- Stacy BrownMt Juliet$719K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.